Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Pancreatic neuroendocrine tumors (pNETs) are the most lethal manifestation in patients with multiple endocrine neoplasia type 1 (MEN1). Tumor size is still regarded as the main prognostic factor and therefore used for surgical decision making.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: van Beek D
Authors: van Beek D, Verkooijen H, Bonsing B, van Eijck C, van Goor H,
Keywords: Multiple endocrine neoplasia type 1, pancreatic neuroendocrine tumor, reliability, agreement, computed tomography, magnetic resonance imaging, endoscopic ultrasonography, pathology,
Introduction: Debulking surgery, TAE and TACE procedures are undertaken in patients with metastatic NETs. Reducing the physical burden of disease may prolong survival and can improve the quality of life of patients. However, there is only limited quality of life data available after surgery despite the fact that is has been used routinely for many years.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Sinclair A, Tanno L, Jarvis E, Ramsey E, Naheed S,
Keywords: Quality of Life, Debulking Surgery, TAE, TACE, Metastatic, NETs,
Introduction: A prediction model to predict recurrence within 5 years after surgery for nonfunctional pancreatic neuroendocrine tumors (PanNets) was recently published. This model includes WHO tumor grade, lymph node status and perineural invasion as predictors.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Heidsma C, Van Dieren S, Gill A, Engelsman A, Strobel O,
Keywords: Prediction model, recurrence, pancreatic neuroendocrine,
Introduction: Sufficient expression of somatostatin receptor type 2 (SST2) in neuroendocrine tumors (NETs) is crucial for treatment with unlabelled somatostatin analogues (SSAs), or peptide receptor radionuclide therapy (PRRT) using radio-labelled SSAs. Impaired prognosis has been described for SST2-negative NET patients, however studies comparing matched SST2-positive and -negative subjects are missing.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Refardt J
Authors: Refardt J, Zandee W, Brabander T, Feelders R, Franssen G,
Keywords: somatostatin receptor type 2, outcome, propensity score analysis, survival,
Introduction: In the 2019 WHO FOR NEN’S classification NETG3 have been distinguished from poorly differentiated neuroendocrine carcinoma (NEC). They are heterogeneous group concerning prognosis and treatment benefit.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Ruiz G, Graselli J, Golubicki M, Rizzol M,
Keywords: G3 NEN, PD-L1, KRAS, BIOMARKERS,